These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 19107243
1. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Porhownik NR, Al-Sharif H, Bshouty Z. Can Respir J; 2008; 15(8):427-30. PubMed ID: 19107243 [Abstract] [Full Text] [Related]
2. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262 [Abstract] [Full Text] [Related]
8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M. Rheumatology (Oxford); 2010 Mar 06; 49(3):490-500. PubMed ID: 20015974 [Abstract] [Full Text] [Related]
15. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Eur Heart J; 2010 May 06; 31(9):1124-31. PubMed ID: 20202971 [Abstract] [Full Text] [Related]
16. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Health Technol Assess; 2009 Oct 06; 13(49):1-320. PubMed ID: 19863849 [Abstract] [Full Text] [Related]